These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 11400322)

  • 1. [Molecular pathogenesis of motor neuron diseases].
    Sobue G
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Feb; 21(1):21-25. PubMed ID: 11400322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.
    Thomas PS; Fraley GS; Damian V; Woodke LB; Zapata F; Sopher BL; Plymate SR; La Spada AR
    Hum Mol Genet; 2006 Jul; 15(14):2225-38. PubMed ID: 16772330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Animal models of neurodegenerative diseases on the road to disease-modifying therapy: spinal and bulbar muscular atrophy].
    Sobue G
    Rinsho Shinkeigaku; 2007 Nov; 47(11):941-3. PubMed ID: 18210842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.
    Banno H; Adachi H; Katsuno M; Suzuki K; Atsuta N; Watanabe H; Tanaka F; Doyu M; Sobue G
    Ann Neurol; 2006 Mar; 59(3):520-6. PubMed ID: 16358333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
    Adachi H; Waza M; Katsuno M; Tanaka F; Doyu M; Sobue G
    Neuropathol Appl Neurobiol; 2007 Apr; 33(2):135-51. PubMed ID: 17359355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA).
    Suzuki K; Kastuno M; Banno H; Sobue G
    Neuropathology; 2009 Aug; 29(4):509-16. PubMed ID: 19486304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of androgen receptor expression and neuronal vulnerability in X-linked spinal and bulbar muscular atrophy].
    Matsuura T
    Hokkaido Igaku Zasshi; 1996 Nov; 71(6):785-99. PubMed ID: 8996845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.
    Tokui K; Adachi H; Waza M; Katsuno M; Minamiyama M; Doi H; Tanaka K; Hamazaki J; Murata S; Tanaka F; Sobue G
    Hum Mol Genet; 2009 Mar; 18(5):898-910. PubMed ID: 19066230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).
    Katsuno M; Tanaka F; Adachi H; Banno H; Suzuki K; Watanabe H; Sobue G
    Prog Neurobiol; 2012 Dec; 99(3):246-56. PubMed ID: 22609045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
    Katsuno M; Adachi H; Waza M; Banno H; Suzuki K; Tanaka F; Doyu M; Sobue G
    Exp Neurol; 2006 Jul; 200(1):8-18. PubMed ID: 16513111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.
    Minamiyama M; Katsuno M; Adachi H; Waza M; Sang C; Kobayashi Y; Tanaka F; Doyu M; Inukai A; Sobue G
    Hum Mol Genet; 2004 Jun; 13(11):1183-92. PubMed ID: 15102712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
    Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
    Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trinucleotide repeat expansion in neurological disease.
    La Spada AR; Paulson HL; Fischbeck KH
    Ann Neurol; 1994 Dec; 36(6):814-22. PubMed ID: 7998766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Sang C; Tanaka F; Inukai A; Doyu M; Sobue G
    Nat Med; 2005 Oct; 11(10):1088-95. PubMed ID: 16155577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of proteolysis in polyglutamine disorders.
    Tarlac V; Storey E
    J Neurosci Res; 2003 Nov; 74(3):406-16. PubMed ID: 14598317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner.
    Kobayashi Y; Miwa S; Merry DE; Kume A; Mei L; Doyu M; Sobue G
    Biochem Biophys Res Commun; 1998 Nov; 252(1):145-50. PubMed ID: 9813160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paradigm shift in clinical trials for neurodegenerative diseases].
    Katsuno M; Banno H; Suzuki K; Takeuchi Y; Sobue G
    Brain Nerve; 2007 Apr; 59(4):367-74. PubMed ID: 17447523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA.
    Suzuki K; Katsuno M; Banno H; Takeuchi Y; Atsuta N; Ito M; Watanabe H; Yamashita F; Hori N; Nakamura T; Hirayama M; Tanaka F; Sobue G
    Brain; 2008 Jan; 131(Pt 1):229-39. PubMed ID: 18056738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.